➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKinsey
Medtronic
Harvard Business School
AstraZeneca

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,504,691


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,504,691 protect, and when does it expire?

Patent 9,504,691 protects XTORO and is included in one NDA.

This patent has twenty patent family members in sixteen countries.

Summary for Patent: 9,504,691
Title:Finafloxacin suspension compositions
Abstract: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a suspension composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin free base or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.
Inventor(s): Boudreaux; Brent G. (Irving, TX), Bridle; Mark J. (Keller, TX), Huynh; Bryan H. (Fort Worth, TX), Ghosh; Malay (Fort Worth, TX), Chowhan; Masood A. (Arlington, TX), Alani; Laman (Fort Worth, TX), Kabra; Bhagwati P. (Euless, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:14/086,651
Patent Claim Types:
see list of patent claims
Composition; Use; Process;

Drugs Protected by US Patent 9,504,691

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF ACUTE OTITIS EXTERNA ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,504,691

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 093813 ⤷  Free Forever Trial
Australia 2013356488 ⤷  Free Forever Trial
Brazil 112015010927 ⤷  Free Forever Trial
Canada 2888641 ⤷  Free Forever Trial
Chile 2015001500 ⤷  Free Forever Trial
China 104869999 ⤷  Free Forever Trial
China 109908081 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Harvard Business School
Merck
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.